Fig. 1: Clinical timeline and resistance phenotyping. | Nature Communications

Fig. 1: Clinical timeline and resistance phenotyping.

From: Rapid evolution and host immunity drive the rise and fall of carbapenem resistance during an acute Pseudomonas aeruginosa infection

Fig. 1

A Bacterial abundance in the lung was assessed by plating out samples of endotracheal aspirate (ETA) on Pseudomonas selective agar (dark blue) and blood agar (total titer, light blue). Rank-order species abundance data is shown for the total bacterial counts. B Bacterial abundance in the gut was assessed on a nominal scale by streaking peri-anal swabs on Pseudomonas selective agar and blood agar (total titer). Day 1 in study is 72 h after ICU admission and corresponds to the first day of patient informed consent. The patient received intravenous treatment with piperacillin/tazobactam (TZP: 4 g/0.5 g IV q8h), meropenem (MEM1: g IV q8h) and colistin (CST 3 million IU IV q8h). Panels C–E show the mean MIC of lung (blue) and intestinal (beige) isolates, as determined by broth microdilution (+/− s.e.m; n = 11 or 12 isolates). Red dashed lines represent the EUCAST clinical breakpoint (01/01/2019 edition). Panel F shows the mean rate of change in viable cell titer of lung isolates following treatment with 2 mg/L of colistin (+/− s.e.m; n = 10-12 isolates). Source data are provided as a Source Data file.

Back to article page